BioAdaptives, Inc. (OTC: BDPT) has outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the planned Aug. 1 commercial launch of XcellaraHeart, the platform’s first commercial application. The company announced the details in a press release, emphasizing the platform’s unique approach to supporting the body’s natural repair mechanisms.
The Xcellara platform combines a stem/progenitor cell mobilization base with tissue-specific ingredients. According to the company, the base formula is supported by a human randomized controlled trial that showed an average 268.8% increase in circulating stem/progenitor-type cells. The tissue-specific ingredients are designed to support the body’s natural signaling pathways and direct those mobilized cells to targeted areas for repair and regeneration.
XcellaraHeart pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. This signaling pathway is crucial for homing stem cells to the heart, potentially aiding in cardiovascular health. BioAdaptives plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.
The announcement underscores the company’s commitment to evidence-based product development. The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two.
BioAdaptives’ flagship Xcellara base formula is described as the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The company’s product line includes seven targeted formulas for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.
The news is significant because it highlights a novel approach in the dietary supplement industry, leveraging clinical evidence to support cellular health. By focusing on mobilizing the body’s own stem cells and directing them to specific tissues, BioAdaptives aims to address a range of wellness concerns. The upcoming launch of XcellaraHeart could set a precedent for how supplements are developed and marketed, emphasizing targeted, science-backed solutions.
For more information about BioAdaptives and its products, visit www.bioadaptives.com.
